Krystal Biotech vs Roivant Sciences
Add, change or remove companies; up to four.
The short version
- Krystal Biotech is the larger business, with $389M of revenue in fiscal 2025 against $8.3M for Roivant Sciences, about 47 times as much.
- Krystal Biotech grew revenue faster (33.9%, against β71.6%).
- Krystal Biotech kept more of each dollar of sales as operating profit (41.5% operating margin, against β6,235.7%).
- Krystal Biotech turned more of its sales into free cash flow (48.6% FCF margin, against β9,183.5%).
- Krystal Biotech earned a higher return on the capital invested in it (43.6%, against β62.6%).
| Latest fiscal year | KRYS Β· FY25 | ROIV Β· FY25 |
|---|---|---|
| Size | ||
| Market cap | $9.6B | $26.3B |
| Revenue | $389M | $8.3M |
| Free cash flow | $189M | β$759M |
| Net income | $205M | β$300M |
| Growth | ||
| Revenue growth | 33.9% | β71.6% |
| 5-year growth | β | β19.0% |
| Share count change | 0.7% | β4.4% |
| Profitability | ||
| Gross margin | β | β |
| Operating margin | 41.5% | β6,235.7% |
| Net margin | 52.6% | β3,629.2% |
| FCF margin | 48.6% | β9,183.5% |
| Return on capital | 43.6% | β62.6% |
| Return on equity | 18.9% | β6.5% |
| Balance sheet | ||
| Net debt | β$828M | β$4.3B |
| Net debt / EBITDA | β5.0x | β |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | 39.0x | β |
| Piotroski F-score | 5 | 1 |
Revenue
FY16
KRYS β
ROIV β
FY17
KRYS β
ROIV β
FY18
KRYS β
ROIV β
FY19
KRYS β
ROIV β
FY20
KRYS β
ROIV $23.8M
FY21
KRYS $0.0M
ROIV $55.3M
FY22
KRYS $0.0M
ROIV $31.5M
FY23
KRYS $50.7M
ROIV $32.7M
FY24
KRYS $291M
ROIV $29.1M
FY25
KRYS $389M
ROIV $8.3M
KRYS
ROIV
Operating margin
FY16
KRYS β
ROIV β
FY17
KRYS β
ROIV β
FY18
KRYS β
ROIV β
FY19
KRYS β
ROIV β
FY20
KRYS β
ROIV β4,500.5%
FY21
KRYS β
ROIV β2,444.8%
FY22
KRYS β
ROIV β2,875.9%
FY23
KRYS β216.2%
ROIV 13,746.9%
FY24
KRYS 22.6%
ROIV β3,453.3%
FY25
KRYS 41.5%
ROIV β6,235.7%
KRYS
ROIV
Free cash flow
FY16
KRYS β$1.3M
ROIV β
FY17
KRYS β$4.1M
ROIV β
FY18
KRYS β$11.7M
ROIV β
FY19
KRYS β$25.1M
ROIV β
FY20
KRYS β$40.9M
ROIV β$558M
FY21
KRYS β$116M
ROIV β$695M
FY22
KRYS β$154M
ROIV β$856M
FY23
KRYS β$101M
ROIV β$767M
FY24
KRYS $119M
ROIV β$844M
FY25
KRYS $189M
ROIV β$759M
KRYS
ROIV
Return on capital
FY16
KRYS β
ROIV β
FY17
KRYS β
ROIV β
FY18
KRYS β
ROIV β
FY19
KRYS β
ROIV β
FY20
KRYS β
ROIV β
FY21
KRYS β61.2%
ROIV β
FY22
KRYS β76.9%
ROIV β286.2%
FY23
KRYS β47.7%
ROIV β
FY24
KRYS 20.7%
ROIV β
FY25
KRYS 43.6%
ROIV β62.6%
KRYS
ROIV
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.